Oscar Health, Inc. (OSCR) Key Metrics
OSCR valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $9.84B
- Enterprise value
- $5.78B
- P/E (TTM)
- 24.7
- Forward P/E
- 588.2
- PEG ratio
- —
- Price / sales
- 0.6 10-yr median 0.3
- Price / book
- 4.6 10-yr median 2.5
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 2.47
OSCR key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsOSCR valuation Price multiples at each fiscal year-end price.
OSCR returns How much profit the business earns on the capital it uses.
OSCR per-share figures Results divided by the shares outstanding at year-end.
OSCR financial health Debt, liquidity and how easily interest is covered.
OSCR efficiency & capital use Working capital cycle and where the cash goes.
OSCR valuation history
OSCR returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
OSCR debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
OSCR cash returned to shareholders
OSCR price vs earnings per share
OSCR key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $3.77B | $3.57B | $2.03B | $522.7M | $1.40B | — | — |
| Enterprise value | $210.0M | $1.72B | −$233.2M | −$2.14B | $11.2M | — | — |
| P/E ratio | — | 140.5 | — | — | — | — | — |
| Price / sales | 0.3 | 0.4 | 0.3 | 0.1 | 0.7 | — | — |
| Price / book | 3.9 | 3.5 | 2.5 | 0.6 | 1.0 | — | — |
| Price / free cash flow | 3.6 | 3.8 | — | 1.5 | — | — | — |
| Price / operating cash flow | 3.4 | 3.7 | — | 1.4 | — | — | — |
| EV / sales | 0.0 | 0.2 | -0.0 | -0.5 | 0.0 | — | — |
| EV / EBITDA | — | 19.3 | — | — | — | — | — |
| EV / free cash flow | 0.2 | 1.8 | — | — | — | — | — |
| Earnings yield | −11.8% | 0.7% | −13.3% | −116.0% | −40.8% | — | — |
| Free cash flow yield | 28.1% | 26.6% | −14.7% | 67.2% | −14.8% | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $14.37 | $13.44 | $9.15 | $2.46 | $7.85 | — | — |
| Per share | |||||||
| Revenue per share | $44.60 | $34.52 | $26.45 | $19.42 | $10.73 | — | — |
| Earnings per share | −$1.69 | $0.10 | −$1.22 | −$2.85 | −$3.20 | — | — |
| Operating cash flow per share | $4.17 | $3.68 | −$1.23 | $1.79 | −$1.02 | — | — |
| Free cash flow per share | $4.03 | $3.57 | −$1.34 | $1.65 | −$1.16 | — | — |
| Cash per share | $15.21 | $8.09 | $11.55 | $13.91 | $9.45 | — | — |
| Book value per share | $3.73 | $3.81 | $3.63 | $4.19 | $7.75 | — | — |
| Tangible book value per share | $3.73 | $3.81 | $3.63 | $4.19 | $6.75 | — | — |
| Capex per share | $0.14 | $0.10 | $0.12 | $0.14 | $0.14 | — | — |
| Debt per share | $1.64 | $1.13 | $1.35 | $1.40 | $1.66 | — | — |
| Shares outstanding | 262.4M | 265.9M | 221.7M | 212.5M | 179.0M | — | — |
| Change in shares outstanding | −1.3% | +19.9% | +4.3% | +18.7% | — | — | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −44.5% | 2.8% | −32.0% | −53.2% | — | — | −30.6% |
| Return on invested capital (ROIC) | — | — | — | — | — | — | −112.4% |
| Return on assets (ROA) | −7.9% | 0.6% | −6.7% | −15.4% | −20.5% | −22.5% | −19.4% |
| Return on tangible assets | −7.0% | 0.5% | −7.5% | −13.4% | −18.2% | −18.7% | −20.2% |
| Free cash flow margin | 9.0% | 10.4% | −5.1% | 8.5% | −10.8% | 35.4% | −34.6% |
| Income quality (OCF / net income) | — | 38.46 | — | — | — | — | — |
| Financial health | |||||||
| Total debt | $430.1M | $299.6M | $298.8M | $298.0M | $297.4M | $142.5M | — |
| Cash & short-term investments | $3.99B | $2.15B | $2.56B | $2.96B | $1.69B | $1.19B | $670.4M |
| Net debt | −$3.56B | −$1.85B | −$2.26B | −$2.66B | −$1.39B | −$1.05B | −$670.4M |
| Debt / equity | 0.44 | 0.30 | 0.37 | 0.33 | 0.21 | — | — |
| Debt / assets | 0.07 | 0.06 | 0.08 | 0.07 | 0.09 | 0.06 | — |
| Net debt / EBITDA | — | −20.74 | — | — | — | — | — |
| Current ratio | 0.95 | 0.90 | — | 1.40 | 1.71 | 2.68 | 1.47 |
| Quick ratio | 0.95 | 0.90 | — | 1.79 | 2.09 | 5.37 | 2.94 |
| Interest coverage | -22.5 | 2.4 | -9.6 | -27.0 | -120.9 | -115.5 | — |
| Working capital | −$249.2M | −$326.5M | $2.25B | $1.18B | $1.14B | $808.4M | $231.4M |
| Invested capital | −$2.58B | −$838.5M | −$1.46B | −$1.77B | −$6.4M | −$2.35B | $182.3M |
| Tangible asset value | $980.7M | $1.02B | $806.1M | $892.4M | $1.21B | −$1.39B | $797.5M |
| Net current asset value | −$731.3M | −$978.9M | −$723.8M | $508.4M | $833.1M | −$2.28B | $231.4M |
| Graham number | — | $2.86 | — | — | — | — | — |
| Graham net-net per share | −$3.90 | −$5.40 | −$6.28 | −$1.83 | $1.32 | — | — |
| Capital allocation | |||||||
| Share buybacks (net) | — | — | — | $0 | $0 | $0 | $3.0M |
| Dividends + buybacks / free cash flow | — | — | — | 0.0% | — | 0.0% | — |
| Capex / revenue | 0.3% | 0.3% | 0.4% | 0.7% | 1.3% | 2.4% | 4.7% |
| Capex / operating cash flow | 3.3% | 2.9% | — | 7.6% | — | 6.3% | — |
| Capex / depreciation | 1.26 | 0.87 | 0.83 | 1.90 | 1.77 | 1.24 | 3.77 |
| Stock-based compensation / revenue | 0.7% | 1.2% | 2.7% | 2.7% | 4.5% | 6.1% | 6.1% |
| SG&A / revenue | 17.5% | 19.1% | 6.9% | 34.4% | 13.8% | 28.3% | 20.0% |
| Efficiency | |||||||
| Days sales outstanding | 11.8 | 16.1 | 51.5 | 97.4 | 108.3 | 46.9 | 36.4 |
| Days of inventory on hand | — | — | -165.6 | — | — | — | — |
| Days payables outstanding | 23.6 | 60.4 | 94.0 | — | — | — | — |
| Cash conversion cycle (days) | -11.8 | -44.2 | -208.2 | — | — | — | — |
| Receivables turnover | 30.85 | 22.65 | 7.09 | 3.75 | 3.37 | 7.78 | 10.03 |
| Payables turnover | 15.43 | 6.05 | 3.88 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset turnover | 2.10 | 2.17 | 1.44 | 1.05 | 0.69 | 0.33 | 0.41 |
| Average receivables | $379.3M | $405.1M | $826.8M | $1.10B | $569.8M | $75.8M | $55.2M |
| Average payables | $649.2M | $1.21B | $1.20B | $1.04B | $599.8M | $487.5M | $494.2M |
| Average inventory | — | — | −$2.11B | −$887.0M | −$952.9M | −$1.01B | −$727.0M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 5.4% | 4.2% | 4.1% |
Computed from OSCR's annual financial statements (latest annual report filed February 13, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
OSCR valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 24.7 and the forward P/E is 588.2. Oscar Health earned a return on equity of −44.5% in fiscal 2025. It ended the year with $430.1 million of debt and $4.0 billion in cash and short-term investments, a net cash position of $3.6 billion.
See the OSCR income statement, the OSCR chart for price history, or the OSCR stock overview for the latest quote and news.
OSCR key metrics FAQ
What is Oscar Health's P/E ratio?
Oscar Health's trailing P/E ratio is 24.7 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 588.2. At the end of fiscal 2025 it was —.
What is Oscar Health's return on equity?
Oscar Health's return on equity (ROE) was −44.5% in fiscal 2025: net income of -$443.2 million on average shareholders' equity of $995.6 million.
How much debt does Oscar Health have?
Oscar Health had total debt of $430.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.44 and more cash than debt.
What is Oscar Health's free cash flow yield?
Oscar Health generated $1.1 billion of free cash flow in fiscal 2025, a free cash flow yield of 28.1% on its market value at year-end ($3.8 billion).
What is Oscar Health's current ratio?
Oscar Health's current ratio was 0.95 at the end of fiscal 2025: current assets were 0.95 times current liabilities.